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The deposition of circulating immune complexes (CIC) in the
glomerulus is thought to be central to the pathogenesis of many
of the glomeruionephritides. In the case of lupus nephritis and
type I membranoproliferative glomerulonephritis (MPGN),
there is considerable evidence for this, in view of the comple-
ment profile indicating reduced levels of the first three reacting
components of complement [1—4] and the granular deposits of
immunoglobulins and complement in the glomerular capillaries
[5—7]. In types II and III MPGN, however, little or no immuno-
globulin is identifiable in the glomerular deposits [7—9], and the
serum complement profile may indicate only alternative path-
way complement activation [3, 9], suggesting that in these
disorders IgG-containing immune complexes capable of activat-
ing the classical complement pathway are either absent or less
abundant.
Several studies of patients with systemic lupus erythemato-
sus have demonstrated the presence of CIC, and the levels have
correlated with activity of the disease [10—13]. The primary
glomerulonephritides are, on the other hand, associated with
low and surprisingly variable levels of CIC [13—18]. The obser-
vations on the nephritides do not answer the question of
whether complexes are present in all three types of MPGN, and
they do not allow assessment of the pathogenicity of the
complexes by correlating their levels with the clinical course.
In the present study, CIC have been measured in MPGN
using a solid-phase Clq radioimmunoassay modified from that
proposed by Hay, Ninehan, and Roitt [19]. The availability of
stored specimens of serum allowed correlation of changes in
CIC levels with the clinical course and with the complement
profile. To provide background for these data, we made mea-
surements in specimens from children with lupus nephritis.
Methods
Serum specimens. Immune complex levels were determined
on either fresh serum or serum stored at —70° C, obtained from
20 normal adults and from children with MPGN or active lupus
nephritis. In all patients, the diagnosis was made from renal
biopsy samples. The criteria for distinguishing the types of
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MPGN have been published [201. Patients were considered to
have developed renal impairment if their serum creatinine
concentrations were equal to or greater than 1.5 mg/dl.
Purification of Clq. Clq was isolated from fresh serum by the
method of Zubler and Lambert [21].
Preparation of anli-IgG. The gamma globulin fraction of goat
antihuman IgG, monospecific for heavy chains, was isolated by
octanoic acid precipitation [22], and pure anti-IgG was prepared
by affinity chromatography using highly purified IgG bound to
Sepharose 4B [231. The pure anti-IgG was radiolabeled with
iodine 125 (Na 125j IMS 30, Amersham Searle) by the method of
David [24]. In the various 1251 anti-IgG preparations used in this
study, 80 to 90% of the 1251 was found to be protein bound.
Heat-aggregated IgG standard. A 5-mi amount of human
Cohn fraction 11(50 mg/mI in 0.15 M sodium chloride) was
centrifuged at x32,000g for 40 mm at 4° C. The supernatant,
containing 44 mg of IgG per milliliter, was heated at 63° C for 10
mm, cooled in ice, centrifuged at 4° C at x32,000g for 20 mm,
and stored in l00-j.i.l aliquots at —70° C until used. The percent-
age of aggregated IgG in this preparation was determined by
sucrose-density gradient analysis. Before each run, an aliquot
of this preparation was thawed, centrifuged at 2,000 rpm for 15
mm, and the upper half of the supernatant added to a previously
unthawed aliquot of pooled normal human serum to prepare
standards. The pooled serum had been stored at —70° C. This
mixture was incubated at 37° C for 30 mm before use.
Immune complex assay. The procedure was a modification of
that described previously [191. Serum samples, in a volume of
50 l, were added to 950 jil of buffer. The buffer contained 0.04
M EDTA as a substitute for preheating the serum to 56° C [251,
and Tween-20 (0.1%) replaced gelatin as a means of blocking
absorption of protein other than Clq to the polystyrene tubes
[261. Each run contained aggregated IgG diluted in pooled NHS
as standards, and results were expressed as aggregated IgG. As
demonstrated by others [16], we found no significant variation
with time in the levels of CIC in serum samples stored at —70° C
and assayed again after 4 to 6 months.
Serum complement levels. Radial immunodiffusion using
monospecific anti-sera made in this laboratory [3, 27, 28] was
used to measure the serum levels of components of the comple-
ment system. Serum was assayed for C3 converting activity
(C3NeF) by measuring the B antigen of C3 in mixtures contain-
ing equal volumes of patient serum and NHS before and after
incubation for 20 mm at 37° C [29].
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Fig. 1. Concentrations f immune complexes in serum from normal
subjects, patients with various types ofMPGN, and patients with active
lupus nephritis. Specimens obtained before initiation of therapy are
indicated by solid circles (•) and those after initiation of therapy by
open circles (0).
Results
The results of measuring immune complexes in serum from
20 normal subjects, 39 patients with MPGN, and 12 patients
with active lupus nephritis are shown in Figure 1. The values for
normal subjects clustered about the zero baseline assigned to
the pool of normal serum standard. The upper limit for normal
subjects was considered to be 8 g/ml. As would be predicted
from the studies of others, complexes were abundant in the
serum samples of most of the patients with active lupus
nephritis. The data for the patients with MPGN were for the
first available specimen of serum. In some of the patients,
treatment had been initiated with immunosuppressive or corti-
costeroid therapy. Complexes is abnormal concentration were
found in 50% of the patients with MPGN. but the concentration
was lower (P < 0.001) than in patients with lupus nephritis.
Among the patients with MPGN, the levels tended to be highest
in those with type I disease, although these differences did not
reach statistical significance.
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Fig. 2. Sermon levels of Clq, properdin, C5. C3. and circulating immune
complexes (C/C) in a /0-year-old patient with MPGN Type I, hfore
and after treatment with an alternate-day prednisone regimen. Dotted
lines indicate the lower limit of normal values for Clq. properdin, CS.
and C3 and the upper limits of normal for dC.
The CIC levels shown in Figure 1 for the MPGN patients
were found to be related to their clinical status, but the
relationship was not that which might be predicted. The correla-
tion is shown in Table 1. When the disease had progressed to a
stage of renal impairment or when the renal impairment devel-
oped within 6 months of obtaining the specimen of serum, only
10% of the patients had detectable complexes. In contrast,
complexes were detected, often in high levels, in 100% of those
in whom the disease produced no urinary abnormality [30] or
produced only hematuria with no or slight proteinuria. Of those
who had more marked proteinuria, usually with hematuria, but
without renal impairment, approximately one half had detect-
able complexes. This correlation held whether or not the patient
had received corticosteroid or immunosuppressive therapy.
No significant correlations were found between levels of C3
or C4 and either the levels or the presence or absence of
circulating immune complexes. One patient with CIC, whose
initial serum lacked significant C3NeF activity, had serial
determinations of C3NeF and CIC that demonstrated a signifi-
cant correlation between the levels of these factors (r = 0.6320,
P < 0.05); there was no correlation between C3NeF values and
CIC levels for the other 14 patients in whom both of these
factors were measured (r = 0.4496, P > 0.1). Among these 14
patients, 2 had elevated levels of CIC and C3NeF, 6 had
elevated levels of CIC and no C3NeF, and 6 had insignificant
levels of both factors.
Levels of CIC were measured serially over periods of I or
more years in 12 patients. In no case was there evidence that
they appeared in showers. Thus, patients initially lacking
complexes did not develop them subsequently. In 4 of the 12
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Fig. 3. Serum levels of C nephritic factor (C3NeF). properdin, (5, (3,
and circulating immune complexes (C/C) in a /5—year—old patient with
type I MPGN, hefre and after treatment with an alternate day
prednisone regimen. Dotted lines indicate the lower limit of normal
values for properdin and CS and the upper limit of normal for CIC and
C3NeF. The lower limit of normal for C3 is 90 mg/dl.
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Fig. 4. Serum levels of' C3, ('5, properdin, and circulating immune
complexes (C/C) in an 8-year-old patient with type III MPGN, before
and ofler treatment with an alternate-day prednisone regimen. The
patient was later discovered to be noncompliant. Dotted lines indicate
the limits of normal values, which are given in Fig. 2.
patients, they were never detected in multiple specimens. In 4
others, they were detected early in the disease but subsequently
disappeared, and in the remaining 4, they had always been
detectable.
In most cases, levels of complexes measured over long
periods showed no correlation with disease activity or with
serum complement levels. In a female patient with type 11
disease, 35 of 36 specimens obtained over a period of 11.5 years
had elevated levels of CIC. C3NeF activity, measured in 10 of
these samples, showed significant correlation (P < 0.05) with
her levels of CIC. But, she has remained well, recently deliver-
ing a normal child without problems. In the patient with type I
disease whose course is illustrated in Figure 2, CIC fell and
serum complement levels concurrently rose. C3NeF could not
be demonstrated in his serum. But, at the time the complement
levels became normal, complexes were still abundant, Two
years after the patient was first seen (August, 1978), complexes
remained present in significant amounts (52 p.g/ml), but a renal
biopsy sample showed marked improvement in glomerular
morphology, with suhendothelial deposits no longer detectable.
A female patient with type I disease, whose course is
illustrated in Figure 3, had both complexes and C3 nephritic
factor detectable in significant amounts over a two-year period,
but no significant correlation was found between her CIC levels
and C3NeF activity. A second renal biopsy sample, performed
2.5 years after she was first seen (August, 1978), showed no
change in glomerular morphology.
The course of a patient with type III disease is shown in
Figure 4. CIC, initially present in low concentration, disap-
peared quickly. However, hypocomplementemia persisted, a
nephrotic syndrome developed, and a subsequent renal biopsy
sample showed progression of the disease.
These observations indicate that in the presence of complex-
es, the glomerular morphology may improve or remain the
same, while, in the absence of complexes, the disease may
progress.
Discussion
The solid-phase Clq assay provides a sensitive and specific
method for the detection of IgG-containing immune complexes
that are reactive with Clq. Unlike fluid-phase Clq assays, the
solid-phase method is not susceptible to interference by sub-
stances such as DNA, C-reactive protein, or bacterial products
that may be present in serum [16]. The original solid-phase Clq
method used heat treatment of the serum sample [191, which
has been shown to aggregate lgG and destroy thermolabile
antigens [251. We and others [16, 311 have found the sensitivity
and reproducibility of the method to be increased by dispensing
with heat treatment.
Previous reports of immune complex measurements in
MPGN have not included serial measurements, and the results
have not been correlated with the clinical status of the patient.
Complexes were detected in the serum samples of II of 21
patients [18], using guinea pig peritoneal macrophage cells and
by the Raji cell test; they were found in 3 of 11 [17]. Results in
other studies are difficult to assess because heated serum was
used [15]. In the present study, the frequency in 39 patients was
46%. There was no difference in the frequency of complexes
among patients with the three types of MPGN. Although the
highest levels were found in type 1, there were no significant
differences in mean levels.
Unfortunately, the levels of complexes correlated poorly
with clinical estimates of disease activity and with serum
complement levels. Glomerular morphology could improve or
remain the same in patients in whom complexes were consis-
tently present in significant amounts over periods of several
years. In the absence of detectable complexes, the disease
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could progress. Similarly, serum complement levels might rise
(Fig. 2), or remain low (Fig. 4) as the level of complexes fell.
The only correlation of CIC with clinical status was the
reverse of that which might be predicted. Complexes were
absent in virtually all patients whose disease had progressed to
actual or incipient renal impairment and were universally
present in those with mild or 'silent" glomerulonephritis. This
observation, in conjunction with the serial studies described
above, would suggest that the complexes are mainly present
before the abnormalities in glomerular morphology become
severe. Artifacts do not appear to be responsible for these
results. Thus, there is no evidence that serum abnormalities
associated with the uremic state inhibit complement detection
by the present method: we have, for example, detected high
levels of complexes in the serum samples of uremic patients
with lupus. Also, the explanation that the uremic state is
immunosuppressive and hence prevents complex formation
hardly applies to the present data because renal function in
most of the ten patients with impairment (Table I) was minimal-
ly compromised with only slightly elevated levels of serum urea
and creatinine. A possible explanation of the results is that the
complexes detected by this method are not nephritogenic, and
that those that are, because of their size, composition, or very
low concentration, escape detection by this method. IgG and
Clq are not frequently found in glomerular deposits of type 11
and type Ill MPGN [7—91, suggesting that the complexes we
detected were not those deposited in the kidney, To be detected
by the solid-phase method, complexes must he reactive with
Clq and contain IgG. If, on the other hand, it were to be
assumed that the complexes detected in the present study are a
factor in pathogenesis, the data might indicate that the course of
the disease is programmed early. Thus, the complexes might
result in a glomerular insult that in turn sets in motion a series of
events, producing a lesion that is self-perpetuating, leading
eventually to glomerular destruction, even though the complex-
es producing the initial insult have disappeared. As this occurs,
the lgG and Clq of the complexes deposited initially may either
be lost or rendered inaccessible to labeled antibody. This
interpretation would have implications relative to the timing
and nature of optimum therapeutic regimens, but further study
obviously will be necessary before drawing conclusions. The
data, however, do indicate that the measurement of complexes
by the solid-phase Clq method in this disease is of minimal
value in diagnosis or in determining prognosis.
Summary. Circulating immune complexes (CIC), measured
by the solid-phase Clq method, were found to be in abnormal
concentration in about half of 39 patients with membranoprolif-
erative glomerulonephritis (MPGN). In contrast, they were
present, usually in higher concentration, in nearly all patients
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with active lupus nephritis. Correlations between clinical
course and CIC levels in patients with MPGN showed that
complexes were always present when the disease was mild or
"silent," but when renal impairment developed or was iricipi-
ent, complexes were nearly always absent. In patients with
disease of intermediate severity, characterized by definite pro-
teinuria but without renal impairment, 50% had complexes The
presence of complexes when glomerular abnormality is relative-
ly slight could be interpreted as indicating that the complexes
measured were not nephritogenic, or that they program subse-
quent events that augment glomerular injury in the absence of
complexes. The measurement of CIC in MPGN appears to have
minimal value both in diagnosis and in determining prognosis.
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